WO1987003300A1 - Enhanced secretion of heterologous proteins by hosts using substituted promoters - Google Patents
Enhanced secretion of heterologous proteins by hosts using substituted promoters Download PDFInfo
- Publication number
- WO1987003300A1 WO1987003300A1 PCT/EP1986/000675 EP8600675W WO8703300A1 WO 1987003300 A1 WO1987003300 A1 WO 1987003300A1 EP 8600675 W EP8600675 W EP 8600675W WO 8703300 A1 WO8703300 A1 WO 8703300A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- host
- promoter
- secretion
- dna
- dna sequence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 132
- 230000028327 secretion Effects 0.000 title claims abstract description 102
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 97
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 73
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 41
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 38
- 108020004414 DNA Proteins 0.000 claims abstract description 23
- 239000013612 plasmid Substances 0.000 claims description 61
- 230000014509 gene expression Effects 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 39
- 108020004999 messenger RNA Proteins 0.000 claims description 23
- 239000013604 expression vector Substances 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- 244000005700 microbiome Species 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108091081024 Start codon Proteins 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 3
- 108010076181 Proinsulin Proteins 0.000 claims description 3
- 241000282898 Sus scrofa Species 0.000 claims description 3
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 108010066381 preproinsulin Proteins 0.000 claims description 3
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims description 2
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 101800005049 Beta-endorphin Proteins 0.000 claims description 2
- 102400000748 Beta-endorphin Human genes 0.000 claims description 2
- 102000004506 Blood Proteins Human genes 0.000 claims description 2
- 108010017384 Blood Proteins Proteins 0.000 claims description 2
- 101800000414 Corticotropin Proteins 0.000 claims description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 2
- 241001524679 Escherichia virus M13 Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 239000000854 Human Growth Hormone Substances 0.000 claims description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 2
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 101100276454 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYC7 gene Proteins 0.000 claims description 2
- 108010056088 Somatostatin Proteins 0.000 claims description 2
- 102000005157 Somatostatin Human genes 0.000 claims description 2
- 241000187747 Streptomyces Species 0.000 claims description 2
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 claims description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 2
- 229960000258 corticotropin Drugs 0.000 claims description 2
- 229940040129 luteinizing hormone Drugs 0.000 claims description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 2
- 229960000553 somatostatin Drugs 0.000 claims description 2
- -1 trpl Proteins 0.000 claims description 2
- 102100021242 Dymeclin Human genes 0.000 claims 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 239000003677 Sheet moulding compound Substances 0.000 claims 1
- 108010006025 bovine growth hormone Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940075439 smac mimetic Drugs 0.000 claims 1
- 108010085238 Actins Proteins 0.000 abstract description 35
- 102000007469 Actins Human genes 0.000 abstract description 33
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 abstract description 18
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 abstract description 18
- 229960000187 tissue plasminogen activator Drugs 0.000 abstract description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 14
- 102000003390 tumor necrosis factor Human genes 0.000 abstract description 14
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 67
- 239000013598 vector Substances 0.000 description 58
- 238000010276 construction Methods 0.000 description 30
- 239000012634 fragment Substances 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 101150050575 URA3 gene Proteins 0.000 description 17
- 230000004927 fusion Effects 0.000 description 15
- 239000002243 precursor Substances 0.000 description 14
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 12
- 108020004511 Recombinant DNA Proteins 0.000 description 12
- 230000012010 growth Effects 0.000 description 11
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000010367 cloning Methods 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 101150007280 LEU2 gene Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 101150012394 PHO5 gene Proteins 0.000 description 5
- 101150033527 TNF gene Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000013606 secretion vector Substances 0.000 description 5
- 101150023453 smc gene Proteins 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 239000012531 culture fluid Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000013587 production medium Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000701822 Bovine papillomavirus Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 102000057041 human TNF Human genes 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 150000002972 pentoses Chemical class 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 108010038049 Mating Factor Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000001573 invertase Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000026447 protein localization Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000009962 secretion pathway Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000007222 ypd medium Substances 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- 101150104241 ACT gene Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- SUQBGKGZERUKII-UHFFFAOYSA-N CCCCCC=[N]12(CC1)CC2 Chemical compound CCCCCC=[N]12(CC1)CC2 SUQBGKGZERUKII-UHFFFAOYSA-N 0.000 description 1
- 102100028991 Cytochrome c1, heme protein, mitochondrial Human genes 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000916041 Homo sapiens Cytochrome c1, heme protein, mitochondrial Proteins 0.000 description 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 1
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 1
- GAOJCVKPIGHTGO-UWVGGRQHSA-N Lys-Arg-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O GAOJCVKPIGHTGO-UWVGGRQHSA-N 0.000 description 1
- NQCJGQHHYZNUDK-DCAQKATOSA-N Lys-Arg-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCN=C(N)N NQCJGQHHYZNUDK-DCAQKATOSA-N 0.000 description 1
- NTSPQIONFJUMJV-AVGNSLFASA-N Lys-Arg-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O NTSPQIONFJUMJV-AVGNSLFASA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 101150002092 SUP45 gene Proteins 0.000 description 1
- 101000947508 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Cytochrome c isoform 1 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Definitions
- This invention relates to expression systems and recombinant DNA molecules that facilitate enhanced secretion of heterologous proteins by hosts, to hosts comprising such recombinant DNA molecules and to methods of producing desired proteins using such hosts.
- Proteins prepared by recombinant DNA methods are sometimes difficult to isolate because the protein must be extracted from the transformed microorganism by means such as cell lysis that typically destroy the microorganism. Obtaining sufficiently pure protein in high yield from such extraction procedures is difficult because of the large number of different organic compounds liberated when lysis takes place.
- secreted protein is more easily separated from the culture medium, and the microorganism can survive the separation process to produce and to secrete more of the desired protein.
- Most proteins naturally secreted by prokaryotes and eukaryotes are initially synthesized in the form of precursors containing an amino-terminal extension several amino acids long. This extension, called a secretion leader or signal sequence, allows the precursor protein to cross the cell membrane of the microorganism and enter the culture medium or periplasmic space of the cell. During secretion, the secretion leader is cleaved from the protein, leading to the presence of mature protein in the culture medium or periplasmic space.
- the present invention solves the foregoing problems by providing expression systems 'that facilitate enhanced secretion of heterologous proteins.
- a promoter of at most intermediate strength and a heterologous DNA secretion signal sequence in a multicopy vector results in a higher yield of a desired protein from the host compared to hosts transformed by a multicopy vector using a strong promoter.
- one embodiment of the present invention comprises a DNA sequence that is an expression and secretion control sequence for producing and secreting a selected protein from a host in which the protein is made, said sequence comprising (a) a promoter that is active in said host and is of at most intermediate strength, and (b) a heterologous DNA secretion signal sequence, recognized by said host, beginning with a start codon, operatively linked to said promoter.
- the expression and secretion control sequence may then be operatively linked to a
- DNA sequence coding for a desired protein and employed to transform a host to produce and secrete the desired protein.
- Yeast is a preferred host, and the actin (ACT) and iso-1-cytochrome c (CYCl) promoters are preferred promoters for yeast hosts.
- ACT actin
- CYCl iso-1-cytochrome c
- S. cerevisiae is the most preferred host.
- the secretion signal sequence is preferably the secretion signal sequence of the MF ⁇ 1 gene.
- the present invention also relates to hosts transformed by the recombinant DNA molecules discussed above and to methods of using transformed hosts in the preparation and secretion of desired proteins.
- Figure 1A shows the structure of the MF ⁇ 1 secretion precursor. Stippled regions indicate spacer regions separating the MF ⁇ 1 repeats. During secretion the secretion leader is cleaved off at the position indicated by the arrow.
- Figure IB shows a general scheme for the construction of a yeast secretion precursor comprising the alpha mating factor (MF ⁇ 1) secretion leader fused to the desired heterologous protein. During secretion, the secretion leader is cleaved at the position indicated by the arrow.
- Figure 2 shows the construction of a gene fusion between the MF ⁇ 1 expression control sequence and the SMC gene and insertion of the MF ⁇ 1/SMC fusion into a yeast expression vector.
- Figure 3 shows two graphs: growth (as reflected by optical density at 600 nm) and SMC levels in the culture fluid of yeast strain BJ1991 transformed with URA3-type expression vectors.
- the CYCl promoter construction (p336/l) is shown by ( ⁇ ); the ACT promoter construction (p364/l) by ( ⁇ ); and the MF ⁇ 1 promoter construction (p446/l) by ( ⁇ ).
- Figure 4A shows the construction of actin promoter fragments ending in EcoRI sites.
- Figure 4B shows the DNA structure of promoter ends for actin and the pEX-5, pEX-7, and pEX-8 vectors.
- Figure 5 shows the construction of SMC secretion vectors based on the ACT and CYCl promoters.
- Figure 6 shows the structure of SMC secretion vectors based on the yeast LEU2 gene.
- Figure 7 shows two graphs: growth (as reflected by optical density at 600 nm) and SMC levels in the culture fluid of yeast strain BJ1991 transformed with LEU2-type expression vectors.
- the CYCl promoter construction (504/1) is shown by ( ⁇ ); the ACT promoter construction (p482/18) by ( ⁇ ); and the MF ⁇ 1 promoter construction (pMF-SMC, rearranged) by ( ⁇ ).
- FIG 8 shows the construction of secretion vectors for TNF.
- Figure 9 shows the construction of secretion vectors for TPA.
- Cloning the process of obtaining a population of organisms or DNA sequences derived from one such organism or sequence by asexual reproduction. Recombinant DNA Molecule or Hybrid DNA -
- Protein - A polypeptide containing a linear series of more than fifty amino acids, e.g., pro insulin, serum albumin, human growth hormone, parathyroid hormone, and interferon. As used herein, however, a protein also comprises a polypeptide chain of fewer than fifty amino acids.
- Polypeptide - A linear series of amino acids connected one to the other by peptide bonds between the amino and carboxy groups of adjacent amino acids.
- Expression The process undergone by a gene to produce a polypeptide or protein. It is a combination of transcription and translation.
- Promoter The region of DNA responsible for binding RNA polymerase to initiate transcription.
- a promoter is located before the ribosome binding site.
- a strong promoter is defined as one that has a strong affinity for RNA polymerase and that would accordingly be expected to aid in obtaining high expression rates.
- a promoter of intermediate strength has a lower affinity for RNA polymerase.
- the strength of a promoter may be affected by the host, the desired protein and the expression vector of the recombinant system. The effects of these factors are more fully discussed below.
- levels of mRNA and levels of expressed protein are proportional to promoter strength.
- promoter strength may affect the number of copies of a multicopy expression vector produced within a given host.
- a host will produce many copies of a multicopy vector that contains an intermediate or weak promoter but will produce fewer copies of a multicopy vector that contains a strong promoter.
- An estimate of the strength of a promoter may be based on the percent of total mRNA in a cell produced by the expression control sequences of that promoter.
- Table 1 shows a list of genes, including their associated promoters and associated mRNA, as described in the literature. A characterization of the promoter strength is also included.
- promoters of glycolytic genes are considered “strong.” Those skilled in the art will understand, however, that promoters may not have the same strength within different strains of a host, with different desired proteins or in different multicopy vectors. In S. cerevisiae, for example, the MF ⁇ 1 promoter is active in MAT ⁇ strains, but inactive in MATa strains. Those skilled in the art will appreciate that promoter strength depends upon many factors.
- Promoters of the present invention should be selected so that the combination of promoter strength and copy number of the multicopy vector provides optimum yields of desired protein. Promoters of intermediate strength provide the best combination of promoter strength with copy number. Weaker promoters, in combination with high copy numbers, are also within the scope of the invention. Strong promoters adversely affect the copy number of the multicopy vectors within the transformed host, and unacceptable yields are obtained from those transformants.
- a promoter should be selected that has maximal strength without significantly reducing plasmid copy number. Generally, a promoter may be considered of at most intermediate strength with respect to a given combination of host, vector and desired protein if the percent of total mRNA in the host corresponding to the promoter is less than 0.3%, and preferably is at most 0.15%.
- Ribosome Binding Site The region of DNA which codes for a site on mRNA which helps the mRNA bind to the ribosome, so that translation can begin.
- a ribosome binding site is located after (downstream from) the promoter and before (upstream from) the translational start signal of the DNA sequence to be expressed to produce the desired protein.
- Gene A DNA sequence which encodes, as a template for mRNA, a sequence of amino acids characteristic of a specific polypeptide or protein.
- Expression Control Sequence A DNA sequence that controls and regulates expression of genes when operatively linked to those genes.
- Such sequences include the lac system, the ⁇ -lactamase system, the trp system, the tac, and trc systems, the major operator and promoter regions of phage ⁇ , the control region of fd coat protein, the early and late promoters of SV40, promoters derived from polyoma virus and adenovirus, metallothionine promoters, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast ⁇ -matihg factors, and other sequences known in the art to control the expression of genes in prokaryotic or eukaryotic cells and their viruses or combinations thereof.
- the gene can be linked to a eukaryotic promoter, such as that for the SV40 early region, coupled to the gene encoding dihydrofolate reductase and selectively amplified in Chinese hamster ovary cells to produce a cell line containing many copies of actively transcribed eukaryotic genes.
- a eukaryotic promoter such as that for the SV40 early region
- the gene encoding dihydrofolate reductase selectively amplified in Chinese hamster ovary cells to produce a cell line containing many copies of actively transcribed eukaryotic genes.
- the precursor is synthesized within a host cell, e.g., preproinsulin, preserum albumin, prehuman growth hormone, preparathyroid hormone, and preinter feron.
- a mature protein is obtained by secreting the precursor through the cell membrane of a host with an attendant loss or clipping of the signal sequence of its precursor.
- RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base.
- the base is linked to the sugar moiety via the glycosidic carbon (l' carbon of the pentose) and that combination of base and sugar is called a nucleoside.
- the base characterizes the nucleotide.
- the four DNA bases are adenine ("A"), guanine ("G”), cytosine ("C”) and thymine (“T”).
- the four RNA bases are A, G, C and uracil ( "U” ) .
- DNA Sequence A linear series of nucleotides connected one to the other by phosphodiester bonds between the 3' and 5' carbons of adjacent pentoses.
- Codon - A DNA sequence of three nucleotides (a triplet) which encodes, through messenger RNA ("mRNA”), an amino acid, a translational start signal or a translational termination signal.
- mRNA messenger RNA
- Plasmid - A non-chromosomal double-stranded DNA sequence comprising an intact "replicon" such that the plasmid is replicated in a host cell.
- the characteristics of that organism are changed or transformed as a result of the DNA of the plasmid.
- a plasmid carrying the gene for tetracycline resistance (Tet R ) transforms a host cell previously sensitive to tetracycline into one which is resistant to it.
- a host cell transformed by a plasmid is called a "transformed host” or a "transformant.”
- Phage or Bacteriophage - Bacterial virus which may include DNA sequences contained in a protein envelope or coat ("capsid").
- Cloning Vehicle A plasmid, phage DNA or other DNA sequence which is able to replicate in a host cell, characterized by one or a small number of endonuclease recognition sites at which its DNA sequence may be cut in a determinable fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production of coat proteins or loss of promoter or binding sites, and which contains a marker suitable for use in the identification of transformed cells, e.g., tetracycline resistance or ampicillin resistance.
- a cloning vehicle is also known as a vector. In the present invention, the vector must be a "multicopy" vector, i.e., capable of producing multiple copies of itself within the host. Single copy vectors, incapable of producing copies, are not within the scope of this invention.
- DNA Signal Sequence A DNA sequence which encodes, as a template for mRNA, a sequence of typically hydrophobic amino acids at the amino terminus of the polypeptide or protein, i.e., a "signal sequence” or "secretion leader sequence” of the protein.
- a DNA signal sequence is operatively linked to and located immediately before the DNA sequence of the desired protein and after its translational start signal (e.g., ATG). It is believed that only a portion of a signal sequence of a precursor of a protein is essential, for the precursor of the protein to be transported through the cell membrane of a host and for proper clipping of the precursor's signal sequence to free the protein during secretion.
- DNA signal sequence includes those DNA sequences that code for that portion of a signal sequence required for secretion.
- an expression system of this invention is operatively linked to a DNA sequence coding. for the desired protein and used to transform an appropriate host. The host may then be cultured under appropriate conditions of growth. The desired protein may then be isolated from the culture. Optimum results will, of course, depend on a number of variables, including the appropriate choice of host, promoter, vector, and growth conditions.
- hosts have been used in recombinant DNA technology and are well known in the art.
- a wide variety of hosts may be useful in the method of this invention. These hosts include for example, bacteria, such as E.coli (for example E.coli HB101 or E. coli MC1061), Bacillus, Streptomyces, and Pseudomonas, fungi, such as yeasts, animal cells, such as CHO cells, mouse, swine, bovine, fowl or fish cells, plant cells in tissue culture, human tissue cells, or other hosts known in the art.
- E.coli for example E.coli HB101 or E. coli MC1061
- Bacillus Streptomyces
- Pseudomonas fungi
- yeasts such as yeasts
- animal cells such as CHO cells, mouse, swine, bovine, fowl or fish cells
- plant cells in tissue culture human tissue cells, or other hosts known in the art.
- an appropriate host is controlled by a number of factors recognized by the art. These include, for example, compatibility with the chosen vector, ease of recovery of the desired protein, expression characteristics, biosafety and costs.
- the host must be able to recognize both the promoter used and the secretion signal sequence used.
- the toxicity of the desired protein on the host must be considered, as well as the viability of the host when transformed by a muticopy vector. No absolute choice of host may be made for a particular recombinant DNA molecule or polypeptide from any of these factors alone. Instead, a balance of these factors must be struck with the realization that not all hosts may be equally effective for expression of a particular DNA sequence operatively linked to a particular expression control sequence.
- yeast is a preferred host, and S. cerevisiae is especially preferred.
- Various promoters may be used in the expression systems of this invention, provided, however, that the promoter is active in the chosen host and is of at most intermediate strength.
- the toxicity of the desired protein to the host affects the promoter choice; for secretion of a less toxic protein, a relatively stronger promoter can be used than for secretion of a more toxic protein.
- the coding region attached to a promoter in a multicopy vector also affects the strength of the promoter.
- the pgk promoter is very strong when attached to its own coding region (PGK), but weak when attached to an alpha interferon gene. J. Mellor et al., "Factors Affecting Heterologous Gene Expression in Saccharomyces cerevisiae," Gene, 33, pp. 215-26 (1985).
- a promoter In choosing a promoter it should also be appreciated that the junction of a strong promoter to a heterologous gene will considerably weaken the strong promoter, as described by Mellor et al., supra. Because promoter strength is affected by so many variables, the fact that a promoter is too strong for use in one host-vector-desired protein combination does not exclude the use of that promoter in a different combination.
- Promoters that may be considered for use in recombinant DNA molecules made from the present invention include, for the yeast S. cerevisiae, the promoters of the ACT (actin) gene, the CYCl (iso-lcytochrome c) gene and the URA3 gene. Kim and Warner, J. Mol. Biol., 165, pp. 79-89 (1983) (mRNA level about 0.008%). For secretion expression systems, strong promoters not suitable for use with
- S. cerevisiae include, for example, the G3PDH and the enolase promoters.
- Preferred promoters in secretion expression systems for use with bacteria such as E.coli and B. subtilis should be of at most intermediate strength. Strong promoters, such as the trp, trc, lac promoters should generally be avoided. Intermediate promoter strength might, however, conveniently be adjusted with regulated promoters, such as the trp or lac promoters, if intermediate inducing growth conditions are chosen.
- promoters that are active during all phases of growth. If the promoters were to be shut off during growth, the adjustment of vector copy number would presumably not take place unless the promoters were induced. Regulated promoters, however, would probably not provide an advantage. Presumably, turning on a strong promoter in a high-copy secretion construction would immediately lyse the host, as in insulin secretion by E.coli.
- a host makes few copies (i.e., low copy numbers) of multicopy vectors if the promoter is strong in the host-vector-desired protein system, and more copies (i.e., higher copy numbers) are made of multicopy vector having a weaker promoter, resulting in improved yields of desired protein.
- a promoter weaker than the CYCl promoter discussed in Example 3 e.g., CYC7 or trpl
- Lowest strength promoters are limited by the promoter strength, and the strongest promoters give only limited copy numbers.
- the multicopy vector and, in particular, the sites chosen therein for insertion of the expression systems of this invention are determined by a variety of factors, e.g., number of sites susceptible to a particular restriction enzyme, size of the protein to be expressed, expression characteristics such as the location of start and stop codons relative to the vector sequences, and other factors recognized by those of skill in the art.
- the choice of a vector is determined by a balance of these factors, not all selections being equally effective for a given case.
- the preferred vectors are plasmids, such as those containing origins of replication derived from chromosomal and non-chromosomal DNA. In the yeast S. cerevisae, the various ARS- and 2 u-type vectors (Botstein et al.) are preferred.
- multicopy plasmids such as ColEl-, pBR322 and RP4 plasmids, or M13 and lambda phage vectors
- non-integrating multicopy vectors such as vectors based on the bovine papilloma virus
- the choice of vector will also be influenced by the chosen promoter, optimal promoter and vector systems will lead to less toxicity of the secreted protein (due to too high copy number or over production based on too strong a promoter) and consequently, higher levels of secretion may be obtained.
- the heterologous secretion signal sequences of this invention must be recognized and correctly processed by the host.
- the signal sequence may comprise a naturally occurring signal sequence, an effective portion of a naturally occurring signal sequence, or a combination of two or more signal sequences or effective portions of signal sequences.
- the signal sequence must be operatively linked to both the promoter and the start signal, ATG.
- the signal sequence begins with the translation start signal.
- the signal sequences is selected from signal sequences already used by the host to aid secretion of its own proteins.
- the desired protein may include any polypeptide or protein, and may include fusions, preproteins, immature proteins or any desired sequence of amino acids.
- desired proteins of this invention include proteins, and other amino acid sequences, that are secretable by some microorganism or cell.
- secretable proteins and other amino acid sequences include serum proteins, analgesic polypeptides such ⁇ -endorphin, somatostatin, insulin, growth hormone (human and bovine), luteinizing hormone, ACTH, pancreatic polypeptide preproteins, preproinsulin, proinsulin, and the A and B chains of insulin.
- the desired proteins of the present invention may comprise proteins and other amino acid sequences naturally secreted into the medium by the selected host.
- the desired protein of the present invention need not be secreted by the selected host. As will be seen in Example 6, the host need only manu- facture the desired protein operatively linked to the chosen signal sequence and correctly process the desired protein into the endoplasmic reticulum. If the desired protein enters the secretion pathway of the host, benefits may be obtained for the desired protein, such as glycosylation. Secretion is, however, the preferred result for the desired protein.
- the present invention may be useful in mammalian cells, if non-integrating, multicopy vectors, such as vectors derived from bovine papilloma virus (D. DiMaio et al., "Bovine PapillomaVirus Vector that Propagates as a Plasmid in Both Mouse and Bacterial Cells," Proc. Nat. Acad. Sci. USA, 79, pp. 30-34 (1982)) are used in conjunction with an intermediate strength promoter.
- bovine papilloma virus D. DiMaio et al., "Bovine PapillomaVirus Vector that Propagates as a Plasmid in Both Mouse and Bacterial Cells," Proc. Nat. Acad. Sci. USA, 79, pp. 30-34 (1982)
- bovine papilloma virus D. DiMaio et al., "Bovine PapillomaVirus Vector that Propagates as a Plasmid in Both Mouse and Bacte
- This example describes the preparation of a transformed yeast which is used in a later example for comparative purposes.
- the transformed yeast of this example has a plasmid containing a MF ⁇ l promoter (which is a strong promoter in yeast as shown below) operatively linked to a MF ⁇ l secretion leader and a DNA sequence coding for SMC.
- a MF ⁇ l promoter which is a strong promoter in yeast as shown below
- Other examples describe the substitution of the ACT and CYCl promoters for the MF ⁇ l promoter, and a comparison of the secretion levels of the variously transformed yeasts.
- other examples describe the preparation of transformed yeasts having plasmids characterized by DNA sequences coding for desired proteins other than SMC.
- the MF ⁇ l secretion precursor comprising a secretion leader and four MF ⁇ l repeats is shown in Figure 1A.
- the stippled regions indicate spacer regions between the MF ⁇ l repeats.
- the pre-MF ⁇ l gene and associated expression control sequence which resided on a 1.7 kb EcoRl fragment, were subcloned into pUC18, the selected cloning vector.
- the result ing plasmid (p220/3) now included an a MF ⁇ l promoter, an MF ⁇ l signal sequence and an MF ⁇ l DNA coding sequence.
- modified oligomer (3') TA TTT TCT CTA GAA CTT CGA ACC (5') original: (3') TA TTT TCT CTC CGA CTT CGA ACC (5') sequence lys arg glu ala glu ala trp
- the resulting plasmid was called p254 ( Figure 2). It was further modified to prevent unintended cleavage at a Bglll site found at the 5' end of the MF ⁇ l promoter. We altered this undesired Bglll site by cleaving with Bglll and filling in the protruding ends using the large (Klenow) fragment of DNA polymerase I and deoxynucleotide triphosphates and subsequent ligation using T4 ligase.
- a StuI site was introduced, in a procedure similar to the mutagenesis described above, at the position corresponding to the same lys-arg cleavage site: modified oligomer: (5') TA AAA AGG CCT CTT GAA GC (3')
- Example 2 Preparation Of ACT/MF ⁇ l/SMC DNA sequences
- Levels of the mRNA coding for actin (D. Gallwitz et al., "The Actin Gene in the Yeast Saccharomyces cerevisiae: 5' and 3' End Mapping, Flanking and Putative Regulatory Sequences," Nucl. Ac. Res., 9, pp. 6339-50 (1981)) suggest that the ACT promoter is a promoter of intermediate strength, see Table 1 . See also Himmelfarb, supra.
- Plasmid pYA30l shown in Figure 4, contains the ACT gene and its associated expression control sequences on a 4 kb EcoRI-BamHI fragment.
- Plasmid pYA301 is a 4 kb EcoRI-BamHI subclone of pYA208 (Gallwitz and Sures, supra) inserted into pBR322.
- Bal31 was cut at the single Xhol site and treated it with Bal31. Following an empirically determined time of Bal31 treatment we cut the plasmid with EcoRI and its protruding ends were filled in using the large (Klenow) fragment of DNA polymerase I.
- the treated plasmid was religated under dilute conditions. Approximately half of the resulting plasmids, identified collectively as p ⁇ 4, contained an EcoRI site. These EcoRI sites had been formed by joining the filled-in EcoRI end to the Bal31 ACT promoter end. Structures of various p ⁇ 4 promoter ends in the vicinity of the ATG start codon of the religated plasmid are shown in Figure 4B.
- the modification was carried out by cutting plasmid p309/1 with PstI and HindiII. The large fragment was isolated and joined to a fragment of pS30/25 resulting from partial digestion of that plasmid with PstI and HindiII.
- the resulting plasmid, p355/1, (ACT promoter/MF ⁇ l secretion leader/SMC structural DNA sequence) was transferred to a yeast shuttle vector, as shown in Figure 5, which resulted in formation of plasmid p364/1. SMC secretion rates by yeast transformed with this plasmid are shown in Figure 3.
- iso-l-cytochrome c amounts to approximately 0.2% of the total cellular protein of yeast, and the encoding mRNA amounts to about 0.05% of the total poly(A) RNA.
- CYCl iso-l-cytochrome c
- the CYCl promoter is thus a weak promoter.
- tripartite SMC expression vectors based on the MF ⁇ l secretion leader and the MF ⁇ l, the ACT, and the CYCl promoters has been described above.
- Each of these vectors contained the yeast URA3 gene for selection in yeast.
- the expression of the plasmid LEU2 gene is low due to a partial deletion; higher copy numbers of the LEU2 type expression vectors are needed to allow the growth of transformants on leucine-free media.
- E. Erhart and C. P. Hollenberg "The Presence of a Defective LEU2 Gene on 2y DNA Recombinant Plasmids of Saccharomyces cervisiae is responsible for. Curing and High Copy Number," J. Bacteriol.,
- yeasts having the URA3 gene or the LEU2 gene in recombinant DNA experiments, see D. Botstein et al., "Sterile Host Yeast (SHY): a Eukaryotic System for Biological Containment for Recombinant DNA Experiments," Gene, 8, pp. 17-24 (1979).
- the LEU2-type vectors by inserting the chosen promoter/MF ⁇ 1 secretion leader/ SMC structural sequence into plasmid pJDB207, using procedures similar to those used with the URA3 plasmids. The structures of the resulting plasmids are shown in Figure -6.
- the plasmid pJDB207 is described in J. D. Beggs, "Multiple-copy Yeast Vectors," Molecular Genetics in Yeast, Alfred Benzon Symposium 16, 383-95 (1981).
- YE439 is a LEU2- type vector with the ACT promoter/MF ⁇ l secretion leader/SMC structural sequence. It was deposited on October 30, 1985 and is identified as DSM 3578.
- YE466 is a LEU2-type vector with the CYCl promoter/MF ⁇ l secretion leader/SMC structural sequence. It was deposited on October 30, 1985 and is identified as DSM 3579. Transformants were grown in the "SD" medium described in F.
- URA3 transformants A high percentage of URA3 transformants actually have few or no URA3 expression plasmids. These unproductive transformants contribute little to overall SMC secretion. Conceivably, a high percentage of URA3 transformants also have high copy numbers and high promoter strength. These transformants would contribute little to SMC secretion because of slow growth and reduced cell viability.
- This suggested mechanism does not apply to LEU2 vectors because the minimum copy number of the LEU2-type vectors in transformants grown in leucine-free media is about 35 (Erhart and Hollenberg. supra).
- the production medium used contains leucine (but no uracil), elevated copy numbers are not required for growth of LEU2 vector-transformants in this medium. Thus, yeast strains transformed with LEU2 appear more homogeneous than URA3 vectors with respect to copy number and mRNA content.
- Table 2 does not give the actual ratio of SMC to actin transcripts, and the numbers are for comparative purposes only. Transformation frequencies for all six plasmid constructions are also shown in Table 2. Aproximately similar transformation frequencies were obtained with allthe URA3-type vectors.
- vector pTNFll (see Figure 8): (1) a
- TNF secretion vector based on the ACT promoter, instead of the MF ⁇ l promoter, is also shown in Figure 8.
- pACT-TNF-EX we ligated the following fragments to construct pACT-TNF-EX: (1) a 1.2 kb Pstl-Hindlll fragment from pTNFll carrying most of the MF ⁇ l secretion leader fused to the TNF gene (described supra); (2) a 0.5 kb BamHI-PstI fragment from p355/1, shown in Figure 5, carrying the ACT promoter and part of the MF ⁇ l leader (described supra); and (3) the 9 kb BamHI-HindIII fragment of pEX-2 (described supra).
- the gene coding for human tissue plasminogen activator carries a convenient Bglll site at a position corresponding to the first amino acid of TPA.
- D. Pennica et al. "Cloning and Expression of Human Tissue-type Plasminogen Activator cDNA in E. coli," Nature, 301, pp. 214-21 (1983).
- a convenient BgllI site at the MF ⁇ l position corresponding to the lys-arg junction.
- the structure of the MF ⁇ l/TPA fusion point in the following constructions is as follows: (5')...AAA AGA TCT TAC...(3') lys arg ser tyr MF ⁇ l TPA
- TPA expressed was biologically active, indicating correct folding. Attempts to express TPA in yeast without a secretion signal sequence produced non-active TPA; and (2) the cell associated TPA was glyco- sylated. Secretion at least into the lumen of the endoplasmic reitculum is necessary for glycosylation to occur.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Lubricants (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Improved secretion of heterologous proteins by hosts such as yeast by using promoters of at most intermediate strength with heterologous DNA secretion signal sequences. A promoter of at most intermediate strength, such as the actin (ACT) or iso-l-cytochrome c (CYCl) promoter in S. cerevisiae is operatively linked to a DNA signal sequence, such as the MFalpha) signal sequence. A DNA sequence for a selected protein, such as somatomedin C (SMC), tissue plasminogen activator (TPA) or tumor necrosis factor (TNF), may be operatively linked to the DNA signal sequence.
Description
ENHANCED SECRETION OF HETEROLOGOUS PROTEINS BY HOSTS USING SUBSTITUTED PROMOTERS
Technical Field Of The Invention This invention relates to expression systems and recombinant DNA molecules that facilitate enhanced secretion of heterologous proteins by hosts, to hosts comprising such recombinant DNA molecules and to methods of producing desired proteins using such hosts.
Background Of The Invention
Proteins prepared by recombinant DNA methods are sometimes difficult to isolate because the protein must be extracted from the transformed microorganism by means such as cell lysis that typically destroy the microorganism. Obtaining sufficiently pure protein in high yield from such extraction procedures is difficult because of the large number of different organic compounds liberated when lysis takes place.
One attractive alternative to typical separation procedures is to have the host secrete the selected protein into its environment. A secreted protein is more easily separated from the culture medium, and the microorganism can survive the separation process to produce and to secrete more of the desired protein.
Most proteins naturally secreted by prokaryotes and eukaryotes are initially synthesized in the form of precursors containing an amino-terminal extension several amino acids long. This extension, called a secretion leader or signal sequence, allows the precursor protein to cross the cell membrane of the microorganism and enter the culture medium or periplasmic space of the cell. During secretion, the secretion leader is cleaved from the protein, leading to the presence of mature protein in the culture medium or periplasmic space.
Although the rate of secretion in bacteria is typically very low, bacterial secretion has been used with recombinant DNA technology. See, for example, United States Patents 4,411,994 and 4,338,397, and Villa-Komaroff et al., Proc. Natl. Acad. Sci. USA, 75, 3727-31 (1978).
The general safety of yeasts and human experience with yeast fermentation have made yeasts desirable candidates for use as hosts in recombinant DNA technology. However, reported attempts to obtain secreted mature proteins from recombinant yeasts have suffered from low yields. See, for example, C. N. Chang et al., "Recognition and Cleavage of Hybrid Invertase Signals and Mature Forms of Human Interferon (IFN-α2) in Yeast," Meeting Abstracts, The Molecular Biology of Yeast, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, p. 393 (1983); B. Meyhack and A. Hinnen, "High Levels of Expression of Foreign Genes Under the Control of the
Yeast PHO5 Promoter," Meeting Abstracts, The Molecular Biology of Yeast, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, p . 156 ( 1983 ) ; S . D. Emr, "An MFα1-SUC2 ( α-Factor-Invertase) Gene Fusion for Study of Protein Localization and Gene Expression in Yeast," Proc. Natl. Acad. Sci. USA, 80, pp. 7080-84 (1983); A. Brake et al., "α-Factor-Directed Synthesis
and Secretion of Mature Foreign Proteins in Saccharomyces cerevisiae," Proc. Natl. Acad. Sci. USA, 81, pp. 4642-46 (1984); G. A. Bitter et al., "Secretion of Foreign Proteins from Saccharomyces cerevisiae Directed by o-Factor Gene Fusions," Proc. Natl. Acad. Sci. USA, 81, pp. 5330-34 (1984); A. Singh, et al., "Synthesis, Secretion and Processing of α-Factor-Interferon Fusion Proteins in Yeast," Nucl. Ac. Res., 12, pp. 8927-38 (1984); European Patent Application 123,228; and European Patent
Application 128,733; and G. Bitter et al, "Secretion of Foreign Proteins from Saccharomyces cerevisiae Directed by α-Factor Phesomone," Nucl. Ac. Res., 11, pp. 4049-63 (1983).
Summary of the Invention
The present invention solves the foregoing problems by providing expression systems 'that facilitate enhanced secretion of heterologous proteins. We have found that using a promoter of at most intermediate strength and a heterologous DNA secretion signal sequence in a multicopy vector results in a higher yield of a desired protein from the host compared to hosts transformed by a multicopy vector using a strong promoter. Thus, one embodiment of the present invention comprises a DNA sequence that is an expression and secretion control sequence for producing and secreting a selected protein from a host in which the protein is made, said sequence comprising (a) a promoter that is active in said host and is of at most intermediate strength, and (b) a heterologous DNA secretion signal sequence, recognized by said host, beginning with a start codon, operatively linked to said promoter. The expression and secretion control sequence may then be operatively linked to a
DNA sequence coding for a desired protein and employed
to transform a host to produce and secrete the desired protein. Yeast is a preferred host, and the actin (ACT) and iso-1-cytochrome c (CYCl) promoters are preferred promoters for yeast hosts. S. cerevisiae is the most preferred host. When the host is S. cerevisiae, the secretion signal sequence is preferably the secretion signal sequence of the MFα1 gene.
The present invention also relates to hosts transformed by the recombinant DNA molecules discussed above and to methods of using transformed hosts in the preparation and secretion of desired proteins.
Brief Description Of The Drawings
Figure 1A shows the structure of the MFα1 secretion precursor. Stippled regions indicate spacer regions separating the MFα1 repeats. During secretion the secretion leader is cleaved off at the position indicated by the arrow.
Figure IB shows a general scheme for the construction of a yeast secretion precursor comprising the alpha mating factor (MFα1) secretion leader fused to the desired heterologous protein. During secretion, the secretion leader is cleaved at the position indicated by the arrow. Figure 2 shows the construction of a gene fusion between the MFα1 expression control sequence and the SMC gene and insertion of the MFα1/SMC fusion into a yeast expression vector.
Figure 3 shows two graphs: growth (as reflected by optical density at 600 nm) and SMC levels in the culture fluid of yeast strain BJ1991 transformed with URA3-type expression vectors. The CYCl promoter construction (p336/l) is shown by (● ); the ACT promoter construction (p364/l) by (▲); and the MFα1 promoter construction (p446/l) by (■).
Figure 4A shows the construction of actin promoter fragments ending in EcoRI sites.
Figure 4B shows the DNA structure of promoter ends for actin and the pEX-5, pEX-7, and pEX-8 vectors.
Figure 5 shows the construction of SMC secretion vectors based on the ACT and CYCl promoters.
Figure 6 shows the structure of SMC secretion vectors based on the yeast LEU2 gene. Figure 7 shows two graphs: growth (as reflected by optical density at 600 nm) and SMC levels in the culture fluid of yeast strain BJ1991 transformed with LEU2-type expression vectors. The CYCl promoter construction (504/1) is shown by (● ); the ACT promoter construction (p482/18) by (▲); and the MFα1 promoter construction (pMF-SMC, rearranged) by (■ ).
Figure 8 shows the construction of secretion vectors for TNF. Figure 9 shows the construction of secretion vectors for TPA.
Detailed Description Of The Invention In order that the invention may be more fully understood, the following detailed description is provided. In this specification, some of the following terms are used:
Cloning - the process of obtaining a population of organisms or DNA sequences derived from one such organism or sequence by asexual reproduction. Recombinant DNA Molecule or Hybrid DNA -
A molecule consisting of sequences of DNA from different genomes which have been joined end-to-end outside of living cells and that can be maintained in living cells. Protein - A polypeptide containing a linear series of more than fifty amino acids, e.g., pro
insulin, serum albumin, human growth hormone, parathyroid hormone, and interferon. As used herein, however, a protein also comprises a polypeptide chain of fewer than fifty amino acids. Polypeptide - A linear series of amino acids connected one to the other by peptide bonds between the amino and carboxy groups of adjacent amino acids.
Expression - The process undergone by a gene to produce a polypeptide or protein. It is a combination of transcription and translation.
Transcription - The process of producing mRNA from a gene.
Translation - The process of producing a protein or polypeptide from mRNA.
Promoter - The region of DNA responsible for binding RNA polymerase to initiate transcription. In bacterial expression systems a promoter is located before the ribosome binding site. A strong promoter is defined as one that has a strong affinity for RNA polymerase and that would accordingly be expected to aid in obtaining high expression rates. A promoter of intermediate strength has a lower affinity for RNA polymerase. In recombinant systems,, the strength of a promoter may be affected by the host, the desired protein and the expression vector of the recombinant system. The effects of these factors are more fully discussed below. In systems that do- not secrete the desired protein, i.e., intracellular expression systems, levels of mRNA and levels of expressed protein are proportional to promoter strength. In intracellular expression systems, no changes of plasmid copy number have been observed with variation of promoter strength. J. Mellor et al, "Factors Affecting Heterologous Gene Expression in Saccharomyces cerevisiae," Gene, 33, pp. 215-26
(1985). In secretion expression systems, we have discovered that promoter strength may affect the number of copies of a multicopy expression vector produced within a given host. In secretion expression systems, a host will produce many copies of a multicopy vector that contains an intermediate or weak promoter but will produce fewer copies of a multicopy vector that contains a strong promoter. An estimate of the strength of a promoter may be based on the percent of total mRNA in a cell produced by the expression control sequences of that promoter. Table 1 shows a list of genes, including their associated promoters and associated mRNA, as described in the literature. A characterization of the promoter strength is also included.
1. J. L. Bennetzen and B. D. Hall, "Codon Selection in Yeast," J. Biol. Chem., 257, pp. 3026-31 (1982)2. C. H. Kim and J. R. Warner, "Messenger RNA for Ribosomal Proteins in Yeast," J. Mol. Biol., 165, pp. 78-89 (1983). 3. H. J. Himmelfarb et al., "Isolation of the SUP45 Omnipotent Suppressor Gene of Saccharomyces cerevisiae and Characterization of its Gene Product," Mol. Cell. Biol., 5, pp. 816-22 (1985).4. M. J. Dobson et al., "Expression in Saccharomyces cerevisiae of Human Interferon-Alpha Directed by TRP1 5' Region," Nucl. Ac. Res., 11, pp. 2287-2302 (1983).
Generally, promoters of glycolytic genes are considered "strong." Those skilled in the art will understand, however, that promoters may not have the same strength within different strains of a host, with different desired proteins or in different multicopy vectors. In S. cerevisiae, for example, the MFα1 promoter is active in MATα strains, but inactive in MATa strains. Those skilled in the art will appreciate that promoter strength depends upon many factors. Merely because a promoter is unacceptable with respect to one combination of host, vector and desired protein does not mean that the promoter will not be acceptable for another combination of host, vector and desired protein. Promoters of the present invention should be selected so that the combination of promoter strength and copy number of the multicopy vector provides optimum yields of desired protein. Promoters of intermediate strength provide the best combination of promoter strength with copy number. Weaker promoters, in combination with high copy numbers, are also within the scope of the invention. Strong promoters adversely affect the copy number of the multicopy vectors within the transformed host, and unacceptable yields are obtained from those transformants. A promoter should be selected that has maximal strength without significantly reducing plasmid copy number. Generally, a promoter may be considered of at most intermediate strength with respect to a given combination of host, vector and desired protein if the percent of total mRNA in the host corresponding to the promoter is less than 0.3%, and preferably is at most 0.15%.
Ribosome Binding Site - The region of DNA which codes for a site on mRNA which helps the mRNA bind to the ribosome, so that translation can begin. In bacterial expression systems, a ribosome binding
site is located after (downstream from) the promoter and before (upstream from) the translational start signal of the DNA sequence to be expressed to produce the desired protein. Gene - A DNA sequence which encodes, as a template for mRNA, a sequence of amino acids characteristic of a specific polypeptide or protein. Expression Control Sequence - A DNA sequence that controls and regulates expression of genes when operatively linked to those genes. Such sequences include the lac system, the β-lactamase system, the trp system, the tac, and trc systems, the major operator and promoter regions of phage λ , the control region of fd coat protein, the early and late promoters of SV40, promoters derived from polyoma virus and adenovirus, metallothionine promoters, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast α-matihg factors, and other sequences known in the art to control the expression of genes in prokaryotic or eukaryotic cells and their viruses or combinations thereof. For mammalian cells, the gene can be linked to a eukaryotic promoter, such as that for the SV40 early region, coupled to the gene encoding dihydrofolate reductase and selectively amplified in Chinese hamster ovary cells to produce a cell line containing many copies of actively transcribed eukaryotic genes. Those skilled in the art will appreciate that not every expression control sequence listed above as an example may be suitable for use with each host, desired protein and vectors combination. Percursor of a Protein - A protein with a signal sequence operatively linked to the protein. Typically, the precursor is synthesized within a host cell, e.g., preproinsulin, preserum albumin, prehuman growth hormone, preparathyroid hormone, and preinter
feron. In accordance with this invention, a mature protein is obtained by secreting the precursor through the cell membrane of a host with an attendant loss or clipping of the signal sequence of its precursor. Nucleotide - A monomeric unit of DNA or
RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (l' carbon of the pentose) and that combination of base and sugar is called a nucleoside. The base characterizes the nucleotide. The four DNA bases are adenine ("A"), guanine ("G"), cytosine ("C") and thymine ("T"). The four RNA bases are A, G, C and uracil ( "U" ) . DNA Sequence - A linear series of nucleotides connected one to the other by phosphodiester bonds between the 3' and 5' carbons of adjacent pentoses.
Codon - A DNA sequence of three nucleotides (a triplet) which encodes, through messenger RNA ("mRNA"), an amino acid, a translational start signal or a translational termination signal. For example, the nucleotide triplets TTA, TTG, CTT, CTC, CTA and CTG encode for the amino acid leucine ("Leu"), TAG, TAA and TGA are translational stop signals and ATG is a translational start signal.
Plasmid - A non-chromosomal double-stranded DNA sequence comprising an intact "replicon" such that the plasmid is replicated in a host cell. When the plasmid is placed within a host organism, the characteristics of that organism are changed or transformed as a result of the DNA of the plasmid. For example, a plasmid carrying the gene for tetracycline resistance (TetR) transforms a host cell previously sensitive to tetracycline into one which is resistant to it. A host cell transformed by a plasmid is called a "transformed host" or a "transformant."
Phage or Bacteriophage - Bacterial virus which may include DNA sequences contained in a protein envelope or coat ("capsid").
Cloning Vehicle - A plasmid, phage DNA or other DNA sequence which is able to replicate in a host cell, characterized by one or a small number of endonuclease recognition sites at which its DNA sequence may be cut in a determinable fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production of coat proteins or loss of promoter or binding sites, and which contains a marker suitable for use in the identification of transformed cells, e.g., tetracycline resistance or ampicillin resistance. A cloning vehicle is also known as a vector. In the present invention, the vector must be a "multicopy" vector, i.e., capable of producing multiple copies of itself within the host. Single copy vectors, incapable of producing copies, are not within the scope of this invention.
Host - An organism which on transformation by a cloning vehicle enables the cloning vehicle to replicate and to accomplish its other biological functions, e.g., the production of polypeptides or proteins through expression of the genes of a plasmid.
DNA Signal Sequence - A DNA sequence which encodes, as a template for mRNA, a sequence of typically hydrophobic amino acids at the amino terminus of the polypeptide or protein, i.e., a "signal sequence" or "secretion leader sequence" of the protein. For secretion, such a DNA signal sequence is operatively linked to and located immediately before the DNA sequence of the desired protein and after its translational start signal (e.g., ATG). It is believed that only a portion of a signal sequence of a precursor of a protein is essential, for the precursor of the protein to be transported
through the cell membrane of a host and for proper clipping of the precursor's signal sequence to free the protein during secretion. Combinations of signal sequences or parts of signal sequences may also be used provided that proper processing takes place in the host. Hence, the term "DNA signal sequence" as used herein includes those DNA sequences that code for that portion of a signal sequence required for secretion. In accordance with this invention, to obtain expression of a desired protein, an expression system of this invention is operatively linked to a DNA sequence coding. for the desired protein and used to transform an appropriate host. The host may then be cultured under appropriate conditions of growth. The desired protein may then be isolated from the culture. Optimum results will, of course, depend on a number of variables, including the appropriate choice of host, promoter, vector, and growth conditions.
Many hosts have been used in recombinant DNA technology and are well known in the art. A wide variety of hosts may be useful in the method of this invention. These hosts include for example, bacteria, such as E.coli (for example E.coli HB101 or E. coli MC1061), Bacillus, Streptomyces, and Pseudomonas, fungi, such as yeasts, animal cells, such as CHO cells, mouse, swine, bovine, fowl or fish cells, plant cells in tissue culture, human tissue cells, or other hosts known in the art.
The selection of an appropriate host is controlled by a number of factors recognized by the art. These include, for example, compatibility with the chosen vector, ease of recovery of the desired protein, expression characteristics, biosafety and costs. In the present invention, the host must be able to recognize both the promoter used and
the secretion signal sequence used. In addition, the toxicity of the desired protein on the host must be considered, as well as the viability of the host when transformed by a muticopy vector. No absolute choice of host may be made for a particular recombinant DNA molecule or polypeptide from any of these factors alone. Instead, a balance of these factors must be struck with the realization that not all hosts may be equally effective for expression of a particular DNA sequence operatively linked to a particular expression control sequence. While the present invention is not limited to S. cerevisiae, yeast is a preferred host, and S. cerevisiae is especially preferred. Various promoters may be used in the expression systems of this invention, provided, however, that the promoter is active in the chosen host and is of at most intermediate strength.
The toxicity of the desired protein to the host affects the promoter choice; for secretion of a less toxic protein, a relatively stronger promoter can be used than for secretion of a more toxic protein. The coding region attached to a promoter in a multicopy vector also affects the strength of the promoter. For example, the pgk promoter is very strong when attached to its own coding region (PGK), but weak when attached to an alpha interferon gene. J. Mellor et al., "Factors Affecting Heterologous Gene Expression in Saccharomyces cerevisiae," Gene, 33, pp. 215-26 (1985). In choosing a promoter it should also be appreciated that the junction of a strong promoter to a heterologous gene will considerably weaken the strong promoter, as described by Mellor et al., supra. Because promoter strength is affected by so many variables, the fact that a promoter is too strong for use in one host-vector-desired protein
combination does not exclude the use of that promoter in a different combination.
Promoters that may be considered for use in recombinant DNA molecules made from the present invention include, for the yeast S. cerevisiae, the promoters of the ACT (actin) gene, the CYCl (iso-lcytochrome c) gene and the URA3 gene. Kim and Warner, J. Mol. Biol., 165, pp. 79-89 (1983) (mRNA level about 0.008%). For secretion expression systems, strong promoters not suitable for use with
S. cerevisiae include, for example, the G3PDH and the enolase promoters.
Preferred promoters in secretion expression systems for use with bacteria such as E.coli and B. subtilis should be of at most intermediate strength. Strong promoters, such as the trp, trc, lac promoters should generally be avoided. Intermediate promoter strength might, however, conveniently be adjusted with regulated promoters, such as the trp or lac promoters, if intermediate inducing growth conditions are chosen.
In the examples, we have used promoters that are active during all phases of growth. If the promoters were to be shut off during growth, the adjustment of vector copy number would presumably not take place unless the promoters were induced. Regulated promoters, however, would probably not provide an advantage. Presumably, turning on a strong promoter in a high-copy secretion construction would immediately lyse the host, as in insulin secretion by E.coli.
As discussed above, we have discovered that, for secretion expression systems, a host makes few copies (i.e., low copy numbers) of multicopy vectors if the promoter is strong in the host-vector-desired protein system, and more copies (i.e., higher copy numbers) are made of multicopy vector having a weaker
promoter, resulting in improved yields of desired protein. However, the use of a promoter weaker than the CYCl promoter discussed in Example 3 (e.g., CYC7 or trpl) will not improve yields due to higher copy numbers, because maximal copy numbers are seen for the CYCl promoter construction (Table 2). Lowest strength promoters are limited by the promoter strength, and the strongest promoters give only limited copy numbers. Though not wishing to be bound by any theory, it appears that high copy numbers combined with strong promoters result in high levels of mRNA, oversecretion of the desired protein or both. In a population of transformants containing cells transformed by vectors having strong promoters, a mixture of copy numbers occurs in the population. Those cells having high copy numbers with strong promoters will stop growing and eventually lyse, while those transformants with lower copy numbers and the same strong promoter will survive. The population will eventually contain only low copy number transformation. See generally T. J. Silhavy, et al., "Mechanisms of Protein Localization," Microbiol. Res., 47, pp. 313-34 (1983).
The multicopy vector and, in particular, the sites chosen therein for insertion of the expression systems of this invention are determined by a variety of factors, e.g., number of sites susceptible to a particular restriction enzyme, size of the protein to be expressed, expression characteristics such as the location of start and stop codons relative to the vector sequences, and other factors recognized by those of skill in the art. The choice of a vector is determined by a balance of these factors, not all selections being equally effective for a given case. The preferred vectors are plasmids, such as those containing origins of replication derived from chromosomal and non-chromosomal DNA. In the yeast
S. cerevisae, the various ARS- and 2 u-type vectors (Botstein et al.) are preferred. In E.coli, multicopy plasmids, such as ColEl-, pBR322 and RP4 plasmids, or M13 and lambda phage vectors, can be used. For animal cells, non-integrating multicopy vectors, such as vectors based on the bovine papilloma virus, are preferred. The choice of vector will also be influenced by the chosen promoter, optimal promoter and vector systems will lead to less toxicity of the secreted protein (due to too high copy number or over production based on too strong a promoter) and consequently, higher levels of secretion may be obtained.
The heterologous secretion signal sequences of this invention must be recognized and correctly processed by the host. The signal sequence may comprise a naturally occurring signal sequence, an effective portion of a naturally occurring signal sequence, or a combination of two or more signal sequences or effective portions of signal sequences. The signal sequence must be operatively linked to both the promoter and the start signal, ATG. Preferably, the signal sequence begins with the translation start signal. In a preferred embodiment, the signal sequences is selected from signal sequences already used by the host to aid secretion of its own proteins.
The desired protein may include any polypeptide or protein, and may include fusions, preproteins, immature proteins or any desired sequence of amino acids. Preferably, however, desired proteins of this invention include proteins, and other amino acid sequences, that are secretable by some microorganism or cell. Examples of such secretable proteins and other amino acid sequences include serum proteins, analgesic polypeptides such β-endorphin, somatostatin, insulin, growth hormone
(human and bovine), luteinizing hormone, ACTH, pancreatic polypeptide preproteins, preproinsulin, proinsulin, and the A and B chains of insulin. The desired proteins of the present invention may comprise proteins and other amino acid sequences naturally secreted into the medium by the selected host.
The desired protein of the present invention need not be secreted by the selected host. As will be seen in Example 6, the host need only manu- facture the desired protein operatively linked to the chosen signal sequence and correctly process the desired protein into the endoplasmic reticulum. If the desired protein enters the secretion pathway of the host, benefits may be obtained for the desired protein, such as glycosylation. Secretion is, however, the preferred result for the desired protein.
The present invention may be useful in mammalian cells, if non-integrating, multicopy vectors, such as vectors derived from bovine papilloma virus (D. DiMaio et al., "Bovine PapillomaVirus Vector that Propagates as a Plasmid in Both Mouse and Bacterial Cells," Proc. Nat. Acad. Sci. USA, 79, pp. 30-34 (1982)) are used in conjunction with an intermediate strength promoter. The following, non-limiting examples will serve to further illustrate the present invention.
Example 1
Preparation Of MFαl/SMC DNA Sequences
This example describes the preparation of a transformed yeast which is used in a later example for comparative purposes. The transformed yeast of this example has a plasmid containing a MFαl promoter (which is a strong promoter in yeast as shown below) operatively linked to a MFαl secretion leader and a DNA sequence coding for SMC. Other examples describe
the substitution of the ACT and CYCl promoters for the MFαl promoter, and a comparison of the secretion levels of the variously transformed yeasts. In addition, other examples describe the preparation of transformed yeasts having plasmids characterized by DNA sequences coding for desired proteins other than SMC.
We first isolated the gene for pre-MFαl and its associated expression control systems and we then operatively linked the MFαl promoter and signal sequence to a DNA sequence for SMC.
The DNA sequence coding for the precursor of MFαl has been sequenced by J. Kurjan and I. Herskowitz, "Structure of a Yeast Pheromone Gene (MFα): A Putative α-Factor Precursor Contains Four Tandem Copies of Mature α-Factor," Cell, 30, pp. 933-43 (1982). We isolated the gene coding for those pre-MFαl and its associated expression control sequences from S. cerevisiae using the library constructed by K. A. Nasmyth, and S. I. Reed, "Isolation of Genes by Complementation in Yeast: Molecular Cloning of a Cell-Cycle Gene," Proc. Natl. Acad. Sci. USA, 77, 2119-23 (1980). Instead of using the cdc28 mutant described in Nasmyth and Reed for isolation and cloning of the cdc28 gene, we used the following oligonucleotide corresponding to amino acids 97 to 102 of the published pre-MFαl:
(5') GTA CAT TGG TTG C/GCC G/A/TGG (3')
The MFαl secretion precursor, comprising a secretion leader and four MFαl repeats is shown in Figure 1A. The stippled regions indicate spacer regions between the MFαl repeats. Before substituting a desired heterologous protein for the four MFαl repeats, as shown in Figure IB, the pre-MFαl gene and associated expression control sequence, which resided on a 1.7 kb EcoRl fragment, were subcloned into pUC18, the selected cloning vector. The result
ing plasmid (p220/3) now included an a MFαl promoter, an MFαl signal sequence and an MFαl DNA coding sequence. In order to isolate the MFαl coding sequence from the MFαl promoter and MFαl signal sequence, we subjected plasmid p220/3 to mutagenesis using the procedure described in B. A. Oostra et al.,
"Transforming Activity of Polyoma Virus Middle-T
Antigen Probed by Site-Directed Mutagenesis," Nature,
304, pp. 456-59 (1983). As a result of the mutagenesis, a convenient Bglll site was introduced at the junction between the secretion leader and the coding sequence for the repeats in the MFαl DNA sequence as follows: modified oligomer: (3') TA TTT TCT CTA GAA CTT CGA ACC (5') original: (3') TA TTT TCT CTC CGA CTT CGA ACC (5') sequence lys arg glu ala glu ala trp
The resulting plasmid was called p254 (Figure 2). It was further modified to prevent unintended cleavage at a Bglll site found at the 5' end of the MFαl promoter. We altered this undesired Bglll site by cleaving with Bglll and filling in the protruding ends using the large (Klenow) fragment of DNA polymerase I and deoxynucleotide triphosphates and subsequent ligation using T4 ligase. To allow for a different cleavage in the plasmid (Examples 5 and 6), a StuI site was introduced, in a procedure similar to the mutagenesis described above, at the position corresponding to the same lys-arg cleavage site: modified oligomer: (5') TA AAA AGG CCT CTT GAA GC (3')
BallI-sequence: (5') TA AAA AGA GAT CTT GAA GC (3') lys arg We then made a MFαl/SMC (secretion leader/ desired protein) fusion by inserting a 500 bp HindiII fragment carrying a synthetic SMC gene starting with
a unique Ncol site into the Hindi 11 site of plasmid p254 (described above) which contained the MFαl promoter and secretion leader and obtained plasmid F-9 as shown in Figure 2 . The synthetic SMC gene is described in G. Buell et al., "Optimizing the Expression in E.coli of a Synthetic Gene Encoding Somatomedin-C (IGF-l)," Nucl. Ac. Res., 13, pp. 1923- 38 (1985). We then cut plasmid F-9 with Bglll and Ncol, with simultaneous S1 treatment and religation to remove the Δ portion of plasmid F-9 and obtain pS30/25, shown in Figure 2. The correct fusion of the MFαl secretion leader and the SMC structual DNA sequence had the following sequence (glycine is the first amino acid of SMC): (secretion leader)-AAA-AGA-GGT-CCA-(SMC) lys arg gly pro As a result the SMC DNA sequence was operatively linked to the MFαl secretion leader so. that the SMC protein would be properly secreted by yeast. As outlined in Figure 2, we introduced the MFα1/SMC fusion into a yeast shuttle vector carrying origins of replication for E. coli and yeast (ori and the 2 μ origin of replication, respectively), as well as selectable markers for both organisms (E. coli: bla; yeast: URA3 ). SMC secretion rates by
S. cerevisiae transformed with this expression vector are shown in Figure 3.
Example 2 Preparation Of ACT/MFαl/SMC DNA sequences The DNA sequence encoding actin in yeast i s described in D . Gallwitz and I . Sures , " Structure of a Split Yeast Gene: Complete Nucleotide Sequence of the Actin Gene in Saccharomyces cerevisiae, " Proc. Natl. Acad. Sci. USA, 77, pp. 2546-50 (1980). Levels of the mRNA coding for actin (D. Gallwitz et al.,
"The Actin Gene in the Yeast Saccharomyces cerevisiae: 5' and 3' End Mapping, Flanking and Putative Regulatory Sequences," Nucl. Ac. Res., 9, pp. 6339-50 (1981)) suggest that the ACT promoter is a promoter of intermediate strength, see Table 1 . See also Himmelfarb, supra.
In order to use the ACT promoter in the constructions of this and the following examples, we placed convenient restriction sites at the end of the promoter. Plasmid pYA30l, shown in Figure 4, contains the ACT gene and its associated expression control sequences on a 4 kb EcoRI-BamHI fragment. Plasmid pYA301 is a 4 kb EcoRI-BamHI subclone of pYA208 (Gallwitz and Sures, supra) inserted into pBR322. We cut plasmid pYA301 at the single Xhol site and treated it with Bal31. Following an empirically determined time of Bal31 treatment we cut the plasmid with EcoRI and its protruding ends were filled in using the large (Klenow) fragment of DNA polymerase I. Finally, the treated plasmid was religated under dilute conditions. Approximately half of the resulting plasmids, identified collectively as pΔ4, contained an EcoRI site. These EcoRI sites had been formed by joining the filled-in EcoRI end to the Bal31 ACT promoter end. Structures of various pΔ4 promoter ends in the vicinity of the ATG start codon of the religated plasmid are shown in Figure 4B. To operatively link the isolated ACT promoter to the MFαl signal sequence SMC fusions, we matched the 3 ' end of the ACT promoter to the amino terminal end of the MFαl/SMC fusion. We accomplished this by introducing an EcoRI site upstream (i.e., earlier in the transcription reading direction) of the ATG start codon of the MFαl secretion leader by carrying out the following mutagenesis using the procedure described in Oostra et al., supra:
modified oligomer: (5') A ATA TAA ACG AAT TCA AGA ATG AG (3') original sequence: (5') A ATA TAA ACG ACC AAA AGA ATG AG (3') We named the resulting plasmid p269/20.
We joined the BamHI-EcoRI fragment of pEX-7 (Fig. 4) isolated above and containing the ACT promoter to the EcoRI-Sall fragment of plasmid p269/20 (which carried the MFαl secretion leader) and inserted the fragment into a BamHI and Sail cut pUC8 vector as shown in Figure 5. We further modified the resulting plasmid (p309/1) by replacing the MFαl secretion leader region of plasmid p309/l by the secretion leader region, joined to the SMC gene, of plasmid pS30/25. Plasmid pS30/25 is shown in Figure 2. The modification was carried out by cutting plasmid p309/1 with PstI and HindiII. The large fragment was isolated and joined to a fragment of pS30/25 resulting from partial digestion of that plasmid with PstI and HindiII. The resulting plasmid, p355/1, (ACT promoter/MFαl secretion leader/SMC structural DNA sequence) was transferred to a yeast shuttle vector, as shown in Figure 5, which resulted in formation of plasmid p364/1. SMC secretion rates by yeast transformed with this plasmid are shown in Figure 3.
EXAMPLE 3
Preparation Of CYCl/MFαl/SMC Plasmids
Under inducing conditions, iso-l-cytochrome c (CYCl) amounts to approximately 0.2% of the total cellular protein of yeast, and the encoding mRNA amounts to about 0.05% of the total poly(A) RNA. R. S. Zitomer and B. D. Hall, "Yeast Cytochrome c Messenger RNA. In Vitro Translation and Specefic Immunoprecipitation of the CYCl Gene Product,"
J. Biol. Chem., 251, 6320-26 (1976). The CYCl promoter is thus a weak promoter.
In order to construct a CYCl promoter/MFαl secretion leader/SMC coding sequence, we isolated an EcoRI-HindiII fragment carrying the MFαl secretion leader correctly fused to the SMC gene from plasmid p355/l, which is shown in Figure 5. We inserted this fragment between the EcoRI and Hindi II sites of pEX-2 to obtain plasmid p446/l (See Figure 5). pEX-2 is described in J. F. Ernst and
R. C. Chan, "Characterization of S. cervisiae Mutants Supersensitive to Aminoglycoside Antibiotics," J. Bacteriol., 163, pp. 8-14 (1985).
The vector p446/l expressed the MFαl/SMC fusion under the control of the CYCl promoter. SMC secretion rates from yeast transformed by this vector are shown in Figure 3.
EXAMPLE 4
Comparison Of Secretion Of SMC Using The MFαl, ACT And CYCl Promoters With Both The
URA3 Gene And The LEU2 Gene on Expression Vectors
The construction of tripartite SMC expression vectors based on the MFαl secretion leader and the MFαl, the ACT, and the CYCl promoters has been described above. Each of these vectors contained the yeast URA3 gene for selection in yeast. We also constructed vectors based on selection using the yeast LEU2 gene. The expression of the plasmid LEU2 gene is low due to a partial deletion; higher copy numbers of the LEU2 type expression vectors are needed to allow the growth of transformants on leucine-free media. E. Erhart and C. P. Hollenberg, "The Presence of a Defective LEU2 Gene on 2y DNA Recombinant Plasmids of Saccharomyces cervisiae is Responsible for. Curing and High Copy Number," J. Bacteriol.,
156, pp. 625-35 (1983). For a discussion of the use
of yeasts having the URA3 gene or the LEU2 gene in recombinant DNA experiments, see D. Botstein et al., "Sterile Host Yeast (SHY): a Eukaryotic System for Biological Containment for Recombinant DNA Experiments," Gene, 8, pp. 17-24 (1979).
We constructed the LEU2-type vectors by inserting the chosen promoter/MFα1 secretion leader/ SMC structural sequence into plasmid pJDB207, using procedures similar to those used with the URA3 plasmids. The structures of the resulting plasmids are shown in Figure -6. The plasmid pJDB207 is described in J. D. Beggs, "Multiple-copy Yeast Vectors," Molecular Genetics in Yeast, Alfred Benzon Symposium 16, 383-95 (1981). We transformed the three URA-type vectors derived from plasmid pEX-2 (which is described in J. F. Ernst and R. C. Chan, supra) and the three LEU2-type vectors into yeast strain BJ1991. Wedeposited two of the recombinant yeast strains in the Deutsche Samulung Von Mikroorganismen (West German Culture Collection). One strain, YE439, is a LEU2- type vector with the ACT promoter/MFαl secretion leader/SMC structural sequence. It was deposited on October 30, 1985 and is identified as DSM 3578. Another strain, YE466, is a LEU2-type vector with the CYCl promoter/MFαl secretion leader/SMC structural sequence. It was deposited on October 30, 1985 and is identified as DSM 3579. Transformants were grown in the "SD" medium described in F. Sherman et al., "Methods in Yeast Genetics," Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1981), containing tryptophan and leucine (for URA3-type vectors), or tryptophan and uracil (for LEU2-type vectors) to an optical density of 2 at 600 nm. We used these cultures to inoculate production medium, consisting of SD medium containing 4% casamino acids and tryptophan (inoculum was 10% of final volume of
productiori medium) At appropriate times during growth, 0.5 ml of the cultures were pelleted using a microfuge. We redissolved the cell pellets in 1/10 the original culture volume by boiling 5 min in sodium dodecyl sulphate (SDS) sample buffer, which is described in U. K. Laemmli, "Cleavage of the Structural Proteins During the Assembly of the Head of Bacteriophage T4, " Nature, 227, pp. 680-85 (1970). We then determined the SMC levels in the redissolved cell pellets and in the culture fluid after dilution, using a radioimmune assay (Nichols Institute Diagnostics, San Juan Capistrano, California).
With all six constructions, less than 10% of the total SMC was cell associated. We purified, SMC present in the culture medium, and analyzed it, finding that the amino terminal and carboxyl terminal amino acids were identical to human SMC and that the biological activity of the secreted SMC was the same as human SMC. Surprisingly, the weakest promoter used, CYCl, resulted in the highest SMC secretion values shown in Figures 3 and 7 and Table 2. This was unexpected because the strongest promoter would have been expected to give the highest secretion values. Unexpectedly, the transformants carrying the CYCl constructions grew slowest and showed a pronounced optimum curve of SMC secretion, indicating the occurrence of cell lysis and SMC degradation (see Figure 7). To determine the reason for the unexpected results, we analyzed SMC plasmid copy number and transcript levels in the transformants described herein after three days in production medium. The results are shown in Table 2. We discovered an inverse relationship between copy number and promoter strength in secretion systems. The secretion system with the weakest promoter (CYCl) proved to have the highest
copy numbers. The MFαl constructs had the lowest copy numbers. The average SMC transcript level proved to be proportional to copy numbers for both URA3 and LEU2 constructs. In turn, with LEU2 constructions, mRNA levels were proportional to secretion levels. With URA3 constructions, no significant increase of SMC secretion levels with increased mRNA was observed. While not wishing to be bound by theory, the URA3 constructs do not appear to have the same effect on the SMC secretion levels because of a high percentage of URA3 plasmid loss.
A high percentage of URA3 transformants actually have few or no URA3 expression plasmids. These unproductive transformants contribute little to overall SMC secretion. Conceivably, a high percentage of URA3 transformants also have high copy numbers and high promoter strength. These transformants would contribute little to SMC secretion because of slow growth and reduced cell viability. This suggested mechanism does not apply to LEU2 vectors because the minimum copy number of the LEU2-type vectors in transformants grown in leucine-free media is about 35 (Erhart and Hollenberg. supra). In addition, since the production medium used contains leucine (but no uracil), elevated copy numbers are not required for growth of LEU2 vector-transformants in this medium. Thus, yeast strains transformed with LEU2 appear more homogeneous than URA3 vectors with respect to copy number and mRNA content.
With the URA3 transcripts, mRNA levels increased
as promoter strength weakened, even though secretion levels remained fairly constant. This trend appears to reflect the lower copy numbers for URA3 constructs. It appears that, for LEU2 transcripts, a copy number of at least 40 is required to obtain minumum levels of mRNA and SMC secretion.
Table 2 does not give the actual ratio of SMC to actin transcripts, and the numbers are for comparative purposes only. Transformation frequencies for all six plasmid constructions are also shown in Table 2. Aproximately similar transformation frequencies were obtained with allthe URA3-type vectors. However, dramatic differences were seen for the LEU2-type vectors, the MFαl promoter constructions could not be transformed in yeast at all, relatively high frequencies were observed for the ACT promoter construction and lower frequencies of transformation, compared to the control (pJDB207) and the ACT construction, were characteristic of the CYC1 construction We did obtain one rare LEU2-type vector transformant with the MPαl construction; however, this transformant contained a rearranged plasmid that directed the synthesis of low amounts of SMC as shown parenthetically in Table 2. This result suggests that the MFαl promoter does not permit a sufficiently high copy number to overcome the effects of the LEU2 defect.
Thus, secretion rate, cell viability, promoter strength and vector copy number appear to be interrelated.
Secretion of TNF
We constructed fusions of the MFαl secretion leader to the gene encoding human tumor necrosis factor (TNF) as shown in Figure 8 by using the procedure described above for MFαl/SMC fusions. We then analyzed the effect of promoter replacement on TNF secretion.
We ligated the following three fragments to construct vector pTNFll (see Figure 8): (1) a
1.2 kb EcoRI-StuI fragment carrying the promoter and the secretion leader of MFαi ending in a StuI site (described supra); (2) a 9 kb EcoRI-Hindi II fragment of pEX-2 carrying the yeast 2y origin of replication and the URA3 gene for selection in yeast (described supra); and (3) a blunt-ended Hindi II fragment (0.9 kb) carrying the TNF gene. Isolation procedures for this third fragment are disclosed in D. Pennica et al., "Human Tumor Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin," Nature, 312, pp. 724-29 (1984). We generated the blunt-ended HindiII fragment by using synthetic oligonucleotide linkers to recreate the 5' end of the TNF gene by extension from an Aval site situated close to the 5' end of the TNF gene (valine is the first amino acid of TNF) . The junction of MFαl to the TNF gene had the following sequence:
(5') ... AAA AGG GTA CGT TCT TCC ... (3') lys arg val arg ser ser MFαl TNF
The construction of a TNF secretion vector based on the ACT promoter, instead of the MFαl promoter, is also shown in Figure 8. We ligated the following fragments to construct pACT-TNF-EX: (1) a 1.2 kb Pstl-Hindlll fragment from pTNFll carrying most of the MFαl secretion leader fused to the TNF
gene (described supra); (2) a 0.5 kb BamHI-PstI fragment from p355/1, shown in Figure 5, carrying the ACT promoter and part of the MFαl leader (described supra); and (3) the 9 kb BamHI-HindIII fragment of pEX-2 (described supra).
We transformed yeast strain BJ1991 with pTNFll or pACT-TNF-EX and selected for Ura+ prototrophs. Transformants were grown selectively in liquid SD medium lacking uracil. Shake flasks containing YPD medium, which is disclosed in F. Sherman et al., supra, were inoculated with minimal cultures (10% final volume) and incubated at 30°C on a rotatory shaker. At appropriate times during incubation, we centrifuged 1 ml samples of the yeast culture for 1 min using a microfuge. We then treated the cell pellet with zymolase to generate spheroplasts. We then lysed the spheroplasts using 1% triton X-100 at 20% of the original culture volume, followed by removal of cell debris by a short centrifugation step. We electrophoresed samples containing TNF on 12.5% SDS-acrylamide gels and transferred the proteins to nitrocellulose by standard methods. We probed the protein blot with rabbit antibodies for human TNF, and we visualized regions of the blot containing TNF/anti-TNF complexes using peroxidasecoupled swine anti-rabbit antibodies. Maximal TNF expression results in the culture fluid and in cell extracts are shown in Table 3. The results indicated that a significant improvement of secretion of TNF was obtained when the MFαl promoter was replaced by the ACT promoter. Only 10-20% of the total TNF produced was cell associated.
EXAMPLE 6
Secretion of TPA
The gene coding for human tissue plasminogen activator (TPA) carries a convenient Bglll site at a position corresponding to the first amino acid of TPA. D. Pennica et al., "Cloning and Expression of Human Tissue-type Plasminogen Activator cDNA in E. coli," Nature, 301, pp. 214-21 (1983). In order to allow correct fusion to the MFα1 secretion leader, we introduced a convenient BgllI site at the MFαl position corresponding to the lys-arg junction. The structure of the MFαl/TPA fusion point in the following constructions is as follows: (5')...AAA AGA TCT TAC...(3') lys arg ser tyr MFαl TPA
We inserted a Bglll fragment carrying the MFα1 promoter and secretion leader into the single Bglll site of the previously constructed vector pPAY4 as shown in Figure 9. In this manner, the PHO5 promoter and secretion leader were replaced by the MFαl promoter and secretion leader. We further modified the resulting expression vector, pMF-TPA, by replacing the PHO5 and MFαl promoters by the ACT promoter, as shown in Figure 9, to obtain expression vector pACT- MF-TPA. The PHO5 promoter present in both TPA constructions is repressed in regular (high-phosphate) production media. Accordingly, the expression results described below are due to the activity of the MFαl
promoter because the tests were carried out in regular (high phosphate) media.
We used each of the expression plasmids, pACT-MF-TPA and pMF-TPA, to transform yeast cells of strain BJ1991, as described above, selecting for
Leu prototrophs. We selectively grew transformants in SD medium. We inoculated shake flasks containing YPD medium with the SD cultures (10% of final volume) and incubated at 30°C. At appropriate times during incubation, we prepared cell extracts as described above in Example 4.
We determined TPA activity in cell fractions by halo formation on fibrinogen-plasminogen-agar plates as described in A. Granelli-Piperno and E. Reich, "A Study of Proteases and Protease-Inhibitor Complexes in Biological Fluids", J. Exp. Med., 148, pp. 223-34 (1978). The results shown in Table 4 indicate that replacement of the MFα1 promoter by the ACT promoter is advantageous in obtaining secretion of heterologous proteins by yeast using alpha mating factor fusions.
As shown in Table 3, most of the TPA produced was cell associated; only 5% of the total TPA produced appeared in the medium. However, the following evidence suggested that yeast TPA had entered the secretion pathway:
(1) the TPA expressed was biologically active, indicating correct folding. Attempts
to express TPA in yeast without a secretion signal sequence produced non-active TPA; and (2) the cell associated TPA was glyco- sylated. Secretion at least into the lumen of the endoplasmic reitculum is necessary for glycosylation to occur.
It will be apparent to those skilled in the art that various modifications may be made in the invention without departing from its spirit or scope, and our basic construction can be altered to provide other embodiments which utilize the processes and compositions of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than the specific embodiments which have been presented as examples.
Claims
1. A DNA sequence comprising:
(a) a promoter of at most intermediate strength; and (b) a DNA secretion signal sequence, beginning with a start codon, heterologous with respect to said promoter and operatively linked to said promoter.
2. The DNA sequence of claim 1, wherein said start codon is ATG.
3. The DNA sequence of claim 1 or 2, wherein said promoter is selected from the group consisting of: the ACT, CYCl, CYC7, trpl, URA3, LEU2, trp and lac promoters.
4. The DNA sequence of any one of the preceding claims, wherein said DNA secretion signal sequence is the MFαl secretion signal sequence.
5. A DNA sequence according to any one of the preceding claims further comprising a DNA sequence coding for a desired protein operatively linked to said DNA secretion signal sequence.
6. The DNA sequence of claim 5, wherein said desired protein is capable of being secreted by a microorganism or cell.
7. The DNA sequence of claim 5 or 6, wherein said desired protein is selected from the group consisting of serum proteins, analgesic polypeptides, β-endorphin, somatostatin, SMC, insulin, human growth hormone, bovine growth hormone, luteinizing hormone, ACTH, pancreatic polypeptide preproteins, TPA, TNF, preproinsulin, proinsulin, the A chain of insulin and the B chain of insulin.
8. A multicopy expression vector comprising a DNA sequence according to any one of claims 1-7.
9. The multicopy expression vector of claim 8, wherein said multicopy expression vector is selected from the group consisting of plasmids and multicopy phages.
10. A host transformed by the DNA sequence of any one of claims 1-7.
11. A host transformed by the multicopy expression vector of any one of claims 8-9.
12. The host of any one of claims 10-11, wherein said multicopy expression vector is selected from the group consisting of: ARS-type plasmids, 2μ-type plasmids, ColEl type plasmids, pBR322, RP4 plasmid, M13 phage and lambda phage.
13. The host of any one of claims 10-12, wherein said promoter does not materially reduce the copy number of said multicopy expression vector in said host.
14. The host of any one of claims 10-13, wherein the expression control sequence of said promoter produces less than 0.3 percent of the total mRNA within said host.
15. The host of claim 14, wherein at most 0.15 percent of the total mRNA within said host is the product of said promoter.
16. The host of any of claims 10-15, wherein said host is selected from the group consisting of: bacteria, fungi, yeasts, animal cells, plant cells in tissue culture or human tissue cells.
17. The host of any one of claims 10-16, wherein said host is selected from the group consisting of: E.coli, Bacillus, Streptomyces,
Pseudomonas, S. cerevisiae, CHO cells, mouse cells, swine cells, bovine cells, fowl cells or fish cells.
18. The host of any one of claims 10-17, wherein said host is yeast.
19. The host of claim 18, wherein said yeast is S. cerevisiae.
20. A method for producing a desired protein, comprising culturing the host of any one of claims 10-19.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP86906826A EP0283475B1 (en) | 1985-11-25 | 1986-11-24 | Enhanced secretion of heterologous proteins by hosts using substituted promoters |
DE3689846T DE3689846T2 (en) | 1985-11-25 | 1986-11-24 | INCREASED EXHIBITION OF HETEROLOGICAL PROTEINS BY HOST CELLS THROUGH THE USE OF SUBSTITUTED PROMOTORS. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB858529014A GB8529014D0 (en) | 1985-11-25 | 1985-11-25 | Enhanced secretion of heterologous proteins |
GB8529014 | 1985-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1987003300A1 true WO1987003300A1 (en) | 1987-06-04 |
Family
ID=10588758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1986/000675 WO1987003300A1 (en) | 1985-11-25 | 1986-11-24 | Enhanced secretion of heterologous proteins by hosts using substituted promoters |
Country Status (8)
Country | Link |
---|---|
US (1) | US5082783A (en) |
EP (1) | EP0283475B1 (en) |
JP (2) | JP2528849B2 (en) |
AT (1) | ATE105865T1 (en) |
CA (1) | CA1318617C (en) |
DE (1) | DE3689846T2 (en) |
GB (1) | GB8529014D0 (en) |
WO (1) | WO1987003300A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0281246A2 (en) * | 1987-02-04 | 1988-09-07 | Invitron Corporation | Method to enhance amplification and expression of foreign genes |
US5030563A (en) * | 1987-07-07 | 1991-07-09 | Genetics Institute, Inc. | Bacterial hypersecretion using mutant repressor sequence |
EP0436597A1 (en) * | 1988-09-02 | 1991-07-17 | Protein Eng Corp | Generation and selection of recombinant varied binding proteins. |
CN1325650C (en) * | 1998-10-16 | 2007-07-11 | 联邦科学及工业研究组织 | Delivery system for porcine somatotropin |
US8067198B2 (en) | 2003-06-25 | 2011-11-29 | Prolume Ltd. | Protein expression system |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326700A (en) * | 1990-11-06 | 1994-07-05 | Eli Lilly And Company | DNA sequences encoding t-PA derivatives with cleavable sites |
DE4107612A1 (en) * | 1991-03-09 | 1992-09-10 | Behringwerke Ag | RECOMBINANT PROTEINS WITH THE IMMUNE REACTIVITY OF HEPATITIS B VIRUS E ANTIGENS (HBEAG), METHODS FOR THEIR PRODUCTION AND THEIR USE IN IMMUNOASSAYS AND VACCINE SUBSTANCES |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
US5925564A (en) * | 1991-11-06 | 1999-07-20 | Baylor College Of Medicine | Expression vector systems and method of use |
WO1995016772A1 (en) | 1993-12-14 | 1995-06-22 | Cornell Research Foundation, Inc. | Adenovirus gene expression system |
EP0822984A4 (en) | 1995-04-27 | 2000-05-03 | Human Genome Sciences Inc | Human tumor necrosis factor receptors |
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
EP0878552A1 (en) * | 1997-05-13 | 1998-11-18 | Erasmus Universiteit Rotterdam | Molecular detection of chromosome aberrations |
WO1999057309A1 (en) * | 1998-05-04 | 1999-11-11 | Dako A/S | Method and probes for the detection of chromosome aberrations |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
WO2005000898A2 (en) * | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
PL2336153T3 (en) | 2003-11-21 | 2016-08-31 | Pfenex Inc | Improved expression systems with SEC-system secretion |
CA2560742A1 (en) * | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
EP2412816B1 (en) | 2004-07-26 | 2014-12-03 | Pfenex Inc. | Process for improved protein expression by strain engineering |
WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
SG154441A1 (en) * | 2006-10-20 | 2009-08-28 | Biogen Idec Inc | Treatment of demyelinating disorders |
US8338376B2 (en) * | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
MX2009004718A (en) | 2006-11-02 | 2009-06-19 | Acceleron Pharma Inc | Alk1 receptor and ligand antagonists and uses thereof. |
CA2677179C (en) | 2007-01-31 | 2016-02-16 | Dow Global Technologies Inc. | Bacterial leader sequences for increased expression |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
EP2142651B1 (en) | 2007-04-27 | 2013-05-22 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US20110020830A1 (en) * | 2008-03-31 | 2011-01-27 | Schneider Jane C | Design for rapidly cloning one or more polypeptide chains into an expression system |
AU2009241755B2 (en) | 2008-05-02 | 2015-10-01 | Acceleron Pharma Inc. | Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage |
JP2010183885A (en) * | 2009-02-13 | 2010-08-26 | Kobe Univ | Method for producing protein and expression vector used therefor |
CN108178789B (en) | 2011-04-20 | 2021-11-02 | 阿塞勒隆制药公司 | Endoglin polypeptides and uses thereof |
KR20140123558A (en) | 2012-02-02 | 2014-10-22 | 악셀레론 파마 인코포레이티드 | Alk1 antagonists and their uses in treating renal cell carcinoma |
BR112015022181A8 (en) | 2013-03-12 | 2018-01-23 | Massachusetts Eye & Ear Infirmary | mullerian inhibiting substance proteins (mis) and their uses for treating diseases |
CN105658672A (en) | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-beta receptor type II variants and uses thereof |
EA035481B1 (en) | 2013-10-25 | 2020-06-23 | Акселерон Фарма, Инк. | Endoglin peptides to treat fibrotic diseases |
WO2015089321A2 (en) | 2013-12-11 | 2015-06-18 | The General Hospital Corporation | Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation |
AU2016301380B2 (en) | 2015-08-04 | 2021-07-01 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
SI3628049T1 (en) | 2017-05-04 | 2023-10-30 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0200590A1 (en) * | 1985-03-25 | 1986-11-05 | Genetica | Method for the microbiological synthesis of human serum albumin |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4411994A (en) * | 1978-06-08 | 1983-10-25 | The President And Fellows Of Harvard College | Protein synthesis |
US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
US4546082A (en) * | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
EP0116201B1 (en) * | 1983-01-12 | 1992-04-22 | Chiron Corporation | Secretory expression in eukaryotes |
ATE220101T1 (en) * | 1983-04-25 | 2002-07-15 | Chiron Corp | HYBRID DNA SYNTHESIS OF MATURE INSULIN-LIKE GROWTH FACTORS |
US4588684A (en) * | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
IL71991A (en) * | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of mature human IGF and EGF via prokaryotic recombinant DNA technology |
-
1985
- 1985-11-25 GB GB858529014A patent/GB8529014D0/en active Pending
-
1986
- 1986-11-24 EP EP86906826A patent/EP0283475B1/en not_active Expired - Lifetime
- 1986-11-24 AT AT86906826T patent/ATE105865T1/en not_active IP Right Cessation
- 1986-11-24 JP JP61506239A patent/JP2528849B2/en not_active Expired - Lifetime
- 1986-11-24 CA CA000523697A patent/CA1318617C/en not_active Expired - Lifetime
- 1986-11-24 DE DE3689846T patent/DE3689846T2/en not_active Expired - Lifetime
- 1986-11-24 WO PCT/EP1986/000675 patent/WO1987003300A1/en active IP Right Grant
-
1989
- 1989-12-18 US US07/452,632 patent/US5082783A/en not_active Expired - Lifetime
-
1994
- 1994-12-07 JP JP6303910A patent/JP2572952B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0200590A1 (en) * | 1985-03-25 | 1986-11-05 | Genetica | Method for the microbiological synthesis of human serum albumin |
Non-Patent Citations (3)
Title |
---|
Gene, Volume 35, 1985, M.A. PETERS et al.: "Expression of a Biologically Active Analogue of Somatomedin-C/Insulin-like Growth Factor I", pages 83-89 see the whole document * |
Nature, Volume 287, 2 October 1980, D.V. GOEDDEL et al.: "Human Leukocyte Interferon Produced by E. Coli is Biologically Active", pages 411-416 see page 414, column 2 * |
Nucleic Acids Research, Volume 11, No. 8, 1983, M.J. DOBSON et al.: "Expression in Saccharomyces Cerevisiae of Human Interferon-alpha Directed by the TRP1 5' Region", pages 2287-2302 see page 2295, paragraph 2; page 2296 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0281246A2 (en) * | 1987-02-04 | 1988-09-07 | Invitron Corporation | Method to enhance amplification and expression of foreign genes |
EP0281246A3 (en) * | 1987-02-04 | 1989-07-12 | Invitron Corporation | Method to enhance amplification and expression of foreign genes |
US5030563A (en) * | 1987-07-07 | 1991-07-09 | Genetics Institute, Inc. | Bacterial hypersecretion using mutant repressor sequence |
EP0436597A1 (en) * | 1988-09-02 | 1991-07-17 | Protein Eng Corp | Generation and selection of recombinant varied binding proteins. |
EP0436597A4 (en) * | 1988-09-02 | 1992-05-20 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
CN1325650C (en) * | 1998-10-16 | 2007-07-11 | 联邦科学及工业研究组织 | Delivery system for porcine somatotropin |
US8067198B2 (en) | 2003-06-25 | 2011-11-29 | Prolume Ltd. | Protein expression system |
US9115364B2 (en) | 2003-06-25 | 2015-08-25 | Prolume Ltd. | Protein expression system |
Also Published As
Publication number | Publication date |
---|---|
JP2572952B2 (en) | 1997-01-16 |
ATE105865T1 (en) | 1994-06-15 |
DE3689846D1 (en) | 1994-06-23 |
DE3689846T2 (en) | 1994-09-22 |
CA1318617C (en) | 1993-06-01 |
GB8529014D0 (en) | 1986-01-02 |
US5082783A (en) | 1992-01-21 |
EP0283475B1 (en) | 1994-05-18 |
JPS63502717A (en) | 1988-10-13 |
EP0283475A1 (en) | 1988-09-28 |
JPH07222595A (en) | 1995-08-22 |
JP2528849B2 (en) | 1996-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5082783A (en) | Enhanced secretion of heterologous proteins by hosts using substituted promoters | |
JP2793215B2 (en) | Improved expression and secretion of heterologous proteins in yeast using truncated .ALPHA.-factor leader sequences | |
US6642029B1 (en) | Hybrid DNA synthesis of mature insulin-like growth factors | |
DE3308215C2 (en) | Expression, processing and secretion of heterologous protein by yeast | |
CA2090969C (en) | Production of insulin-like growth factor-1 in methylotrophic yeast cells | |
EP0123544A2 (en) | Process for expressing heterologous protein in yeast, expression vehicles and yeast organisms therefor | |
ERNST | Improved secretion of heterologous proteins by Saccharomyces cerevisiae: effects of promoter substitution in alpha-factor fusions | |
EP0347928A2 (en) | Pichia pastoris alcohol oxidase II regulatory region | |
US5187261A (en) | Process for the preparation of mature human serum albumin | |
JPH07110233B2 (en) | Releasable East Promoter | |
AU667852B2 (en) | Novel DNA molecules and hosts | |
JP2511251B2 (en) | Gene system for the production of mature insulin | |
WO1992013951A1 (en) | Production of human serum albumin in methylotrophic yeast cells | |
AU665034B2 (en) | Production of human parathyroid hormone from microorganisms | |
EP0127304A1 (en) | Process for producing heterologous protein in yeast, expression vehicle therefor, and yeast transformed therewith | |
JPS6344890A (en) | Development system of filamentous fungi | |
JPH03504561A (en) | Production and purification of recombinant human interleukin-3 and its mutant proteins | |
NO813759L (en) | PLASMID, PROCEDURE FOR MANUFACTURING SUCH A PRODUCT, AND USE THEREOF | |
Ludwig et al. | High-level heterologous gene expression in Saccharomyces cerevisiae from a stable 2μm plasmid system | |
US5521093A (en) | Yeast vector coding for heterologous gene fusions linked via KEX2 cleavage site and coding for truncated KEX2 genes | |
US6183989B1 (en) | Process for making desired polypeptides in yeast | |
US5104795A (en) | Shortened phosphoglycerate kinase promoter | |
EP0310137B1 (en) | BAR1 secretion signal | |
US5879926A (en) | Yeast strains for the production of mature heterologous proteins, especially hirudin | |
EP0245479B1 (en) | Shortened phosphoglycerate kinase promoter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1986906826 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1986906826 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1986906826 Country of ref document: EP |